Nonalcoholic Steatohepatitis
📧 Sign up to get email alerts when something new happens for Nonalcoholic Steatohepatitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-21Clinical Trial Results: A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) [Phase 2]
Phase 2 study results for efruxifermin in patients with compensated cirrhosis due to NASH have been completed and results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
A National Institute of Allergy and Infectious Diseases-sponsored trial evaluating liver fibrosis and steatohepatitis in HIV-infected patien…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Novel MRE Technique to Assess a Risk Factor for Liver Cancer
A clinical trial is evaluating a novel magnetic resonance elastography technique as a potential tool to assess a risk factor for liver cance…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
This completed study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) evaluated the response to COV…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis [NA]
A completed clinical trial evaluated the feasibility, safety, and acceptability of a mobile health-delivered exercise training program in pa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Semaglutide vs Sitagliptin [Phase 4]
Phase 4 clinical trial comparing semaglutide and sitagliptin in liver transplant recipients with diabetes and fatty liver disease. Enrollmen…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Vitamin E Dosing Study [Phase 2]
A Phase II trial evaluating different dosing regimens of vitamin E for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis has…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
A pediatric imaging trial using free-breathing MRI and MR elastography to quantify body composition and liver disease has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) [Phase 2]
Phase 2 study MK-6024-017 evaluating efinopegdutide in compensated cirrhosis due to nonalcoholic fatty liver disease and nonalcoholic steato…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis [Phase 2, Phase 3]
The Phase 2/Phase 3 trial evaluating belapectin for the prevention of esophageal varices in NASH-related cirrhosis has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study [Phase 2]
Phase 2 RELIEF-NAFLD trial update evaluating lisinopril to prevent progression of non-alcoholic fatty liver disease and nonalcoholic steatoh…
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) [Phase 2]
Phase 2 study of efinopegdutide in participants with precirrhotic nonalcoholic steatohepatitis (NAFLD/NASH) has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
The GREAT1.0 genomic resources study is currently suspended, with no trial results reported at this time.
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) [Phase 2]
A Phase 2 study evaluating BIO89-100 in adults with biopsy-confirmed nonalcoholic steatohepatitis has completed, and the results have been p…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease [Phase 2]
Phase 2 trial studying ibutamoren for nonalcoholic fatty liver disease has completed and posted results. The study was sponsored by Massachu…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) [Phase 2]
A Phase 2 trial evaluating the efficacy and safety of pemvidutide in nonalcoholic steatohepatitis has completed, with results on its perform…
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: Repeatability and Reproducibility of Multiparametric MRI
A clinical trial update reports on the repeatability and reproducibility of multiparametric MRI for evaluating liver diseases across several…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) [Phase 2]
Phase 2 study evaluating semaglutide alone and in combination with cilofexor and firsocostat for cirrhosis due to nonalcoholic steatohepatit…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects [Phase 2]
This clinical trial update notes the Phase 2 study of HM15211 (Efocipegtrutide) for nonalcoholic steatohepatitis is ongoing but currently no…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension [Phase 2]
Boston Pharmaceuticals completed a Phase 2 study of BOS-580 in obese subjects at risk for or with biopsy-confirmed nonalcoholic steatohepati…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis [Phase 2]
Phase 2 trial evaluating AZD2693 in carriers of the PNPLA3 148M risk allele with non-cirrhotic nonalcoholic steatohepatitis with fibrosis ha…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis [Phase 2]
A completed Phase 2 clinical trial evaluating saroglitazar magnesium for nonalcoholic steatohepatitis with fibrosis.
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH [Phase 2]
Phase 2 dose exploration trial of GSK4532990 in participants with non-alcoholic fatty liver disease, including NASH or suspected NASH, has c…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [Phase 3]
Phase 3 study evaluating efruxifermin in adults with noninvasively diagnosed nonalcoholic steatohepatitis and nonalcoholic fatty liver disea…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis [Phase 2]
This clinical trial update reports results from a Phase 2 study evaluating the safety and efficacy of cotadutide given by subcutaneous injec…